Baxter International (NYSE:BAX) updated its FY 2020
Pre-Market earnings guidance on Thursday. The company provided EPS guidance of 3.00-3.10 for the period. The company issued revenue guidance of $11.248-11.476 billion, compared to the consensus revenue estimate of $11.72 billion.Baxter International also updated its FY20 guidance to $3.00-3.10 EPS.
Several analysts have recently commented on the company. KeyCorp increased their price objective on Baxter International from $92.00 to $98.00 and gave the company an overweight rating in a report on Friday, May 1st. Morgan Stanley reduced their target price on Baxter International from $95.00 to $90.00 and set an equal weight rating for the company in a research note on Friday. JPMorgan Chase & Co. raised their target price on Baxter International from $94.00 to $96.00 and gave the stock an overweight rating in a research note on Tuesday, April 28th. Oppenheimer restated a buy rating on shares of Baxter International in a research note on Thursday. Finally, Barclays restated a hold rating and issued a $84.00 target price on shares of Baxter International in a research note on Tuesday, April 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $96.72.
BAX stock opened at $86.38 on Friday. The company has a current ratio of 2.74, a quick ratio of 2.19 and a debt-to-equity ratio of 0.84. Baxter International has a 12-month low of $69.10 and a 12-month high of $95.19. The stock has a market cap of $43.62 billion, a price-to-earnings ratio of 26.10, a PEG ratio of 2.75 and a beta of 0.84. The business’s 50-day moving average is $86.00 and its 200 day moving average is $86.95.
Baxter International (NYSE:BAX) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.64 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.71 by ($0.07). The company had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.86 billion. Baxter International had a return on equity of 21.02% and a net margin of 8.10%. The company’s revenue for the quarter was down 4.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.89 earnings per share. As a group, equities analysts forecast that Baxter International will post 3.05 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Monday, August 31st will be issued a dividend of $0.245 per share. This represents a $0.98 annualized dividend and a dividend yield of 1.13%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International’s dividend payout ratio is currently 29.61%.
In other news, SVP Andrew Frye sold 3,742 shares of Baxter International stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $91.00, for a total transaction of $340,522.00. Following the sale, the senior vice president now owns 16,216 shares of the company’s stock, valued at approximately $1,475,656. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John D. Forsyth sold 1,500 shares of Baxter International stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $82.95, for a total transaction of $124,425.00. Following the sale, the director now directly owns 35,398 shares in the company, valued at approximately $2,936,264.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 77,583 shares of company stock worth $6,613,932. Insiders own 0.13% of the company’s stock.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Article: What is a growth and income fund?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.